This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, R. Articles by Ladisch, S. Search for Related Content PubMed PubMed Citation Articles by Li, R. Articles by Ladisch, S.

Abrogation of Shedding of Immunosuppressive Neuroblastoma Gangliosides¹

Center for Cancer and Transplantation Biology, Children's Research Institute, and Departments of Pediatrics and Biochemistry/Molecular Biology, George Washington University School of Medicine, Washington, DC 20010

Shedding of tumor cell gangliosides may contribute to tumor cell escape from host immune destruction. Thus, it would be of interest to block the shedding of these immunosuppressive molecules. To this end, we studied a ceramide analogue, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP). D-PDMP is a potent inhibitor of glucosylceramide synthase and thereby the synthesis of cellular glycosphingolipids. Exposure of LAN-5 human neuroblastoma cells to 10 µM D-PDMP for 5 days almost completely abolished the shedding of gangliosides (from 240 to 8 pmol/10⁸ cells/h), whereas cellular ganglioside synthesis was reduced by 90%. A shorter (3-day) treatment of LAN-5 cells with 10 µM D-PDMP was already effective in inhibiting shedding (by 86%) even while the cellular ganglioside content was still high. Specificity was evidence by the only minimal effect of D-PDMP on the synthesis of sphingomyelin and phosphatidylcholine. Therefore, certain pharmacological agents, such as D-PDMP, may be useful in abrogating tumor ganglioside shedding and its consequent biological effects in vivo.

¹ This work was supported by Grants CA61010 and CA42361 from the National Cancer Institute and by the Stewart Trust.

² To whom requests for reprints should be addressed, at Center for Cancer and Transplantation Biology, Children's Research Institute, 111 Michigan Avenue NW, Washington, DC 20010. Phone: (202) 884-3898; Fax: (202) 884-3929.

Received 6/26/96. Accepted 8/29/96.

This article has been cited by other articles:

				C. S. Berenson, M. A. Gallery, J. M. Smigiera, and R. H. Rasp The role of ceramide of human macrophage gangliosides in activation of human macrophages J. Leukoc. Biol., September 1, 2002; 72(3): 492 - 502. [Abstract] [Full Text] [PDF]

				V. Sriram, S. Cho, P. Li, P. W. O'Donnell, C. Dunn, K. Hayakawa, J. S. Blum, and R. R. Brutkiewicz Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells PNAS, June 11, 2002; 99(12): 8197 - 8202. [Abstract] [Full Text] [PDF]

				W. Deng, R. Li, M. Guerrera, Y. Liu, and S. Ladisch Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation Glycobiology, March 1, 2002; 12(3): 145 - 152. [Abstract] [Full Text] [PDF]

				G. V. Shurin, M. R. Shurin, S. Bykovskaia, J. Shogan, M. T. Lotze, and E. M. Barksdale Jr. Neuroblastoma-derived Gangliosides Inhibit Dendritic Cell Generation and Function Cancer Res., January 1, 2001; 61(1): 363 - 369. [Abstract] [Full Text]

				W. Deng, R. Li, and S. Ladisch Influence of Cellular Ganglioside Depletion on Tumor Formation J Natl Cancer Inst, June 7, 2000; 92(11): 912 - 917. [Abstract] [Full Text] [PDF]

				R. McKallip, R. Li, and S. Ladisch Tumor Gangliosides Inhibit the Tumor-Specific Immune Response J. Immunol., October 1, 1999; 163(7): 3718 - 3726. [Abstract] [Full Text] [PDF]